MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

@article{Lennerz2011METAI,
  title={MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.},
  author={Jochen K Lennerz and Eunice Lee Kwak and Allison Ackerman and Michael Michael and Stephen B. Fox and Kristin E Bergethon and Gregory Yves Lauwers and James G. Christensen and Keith D. Wilner and Daniel A. Haber and Ravi Salgia and Yung-jue Bang and Jeffrey T. Clark and Benjamin J. Solomon and Anthony John Iafrate},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 36},
  pages={4803-10}
}
PURPOSE Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow-up and reported the clinical response of four additional patients with MET-amplified tumors to the small molecule inhibitor crizotinib as part of an expanded phase I cohort study. PATIENTS AND METHODS From 2007 to 2009, patients with GEC were genetically screened as a consecutive series of 489 tumors (stages 0, I, and II… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 185 extracted citations

Similar Papers

Loading similar papers…